MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/annrheumdis-2014-205351

Медицинская библиотека · Annals of the rheumatic diseases · 2014

Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.

Brunner Hermine I, Ruperto Nicolino, Zuber Zbigniew, Keane Caroline, Harari Olivier, Kenwright Andrew, Lu Peng, Cuttica Ruben, Keltsev Vladimir, Xavier Ricardo M, Calvo Inmaculada, Nikishina Irina, Rubio-Pérez Nadina, Alexeeva Ekaterina, Chasnyk Vyacheslav, Horneff Gerd, Opoka-Winiarska Violetta, Quartier Pierre, Silva Clovis A, Silverman Earl, Spindler Alberto, Baildam Eileen, Gámir M Luz, Martin Alan, Rietschel Christoph, Siri Daniel, Smolewska Elzbieta, Lovell Daniel, Martini Alberto, De Benedetti Fabrizio, Paediatric Rheumatology International Trials Organisation PRINTO, Pediatric Rheumatology Collaborative Study Group (PRCSG)

Клиническое исследование III фазыСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

To evaluate the interleukin-6 receptor inhibitor tocilizumab for the treatment of patients with polyarticular-course juvenile idiopathic arthritis (pcJIA).

METHODS

This three-part, randomised, placebo-controlled, double-blind withdrawal study (NCT00988221) included patients who had active pcJIA for ≥6 months and inadequate responses to methotrexate. During part 1, patients received open-label tocilizumab every 4 weeks (8 or 10 mg/kg for body weight (BW) <30 kg; 8 mg/kg for BW ≥30 kg). At week 16, patients with ≥JIA-American College of Rheumatology (ACR) 30 improvement entered the 24-week, double-blind part 2 after randomisation 1:1 to placebo or tocilizumab (stratified by methotrexate and steroid background therapy) for evaluation of the primary end point: JIA flare, compared with week 16. Patients flaring or completing part 2 received open-label tocilizumab.

RESULTS

In part 1, 188 patients received tocilizumab (<30 kg: 10 mg/kg (n=35) or 8 mg/kg (n=34); ≥30 kg: n=119). In part 2, 163 patients received tocilizumab (n=82) or placebo (n=81). JIA flare occurred in 48.1% of patients on placebo versus 25.6% continuing tocilizumab (difference in means adjusted for stratification: -0.21; 95% CI -0.35 to -0.08; p=0.0024). At the end of part 2, 64.6% and 45.1% of patients receiving tocilizumab had JIA-ACR70 and JIA-ACR90 responses, respectively. Rates/100 patient-years (PY) of adverse events (AEs) and serious AEs (SAEs) were 480 and 12.5, respectively; infections were the most common SAE (4.9/100 PY).

CONCLUSIONS

Tocilizumab treatment results in significant improvement, maintained over time, of pcJIA signs and symptoms and has a safety profile consistent with that for adults with rheumatoid arthritis.

TRIAL REGISTRATION NUMBER: NCT00988221.

Для цитирования: Brunner Hermine I, Ruperto Nicolino, Zuber Zbigniew, Keane Caroline, Harari Olivier, Kenwright Andrew, Lu Peng, Cuttica Ruben, Keltsev Vladimir, Xavier Ricardo M, Calvo Inmaculada, Nikishina Irina, Rubio-Pérez Nadina, Alexeeva Ekaterina, Chasnyk Vyacheslav, Horneff Gerd, Opoka-Winiarska Violetta, Quartier Pierre, Silva Clovis A, Silverman Earl, Spindler Alberto, Baildam Eileen, Gámir M Luz, Martin Alan, Rietschel Christoph, Siri Daniel, Smolewska Elzbieta, Lovell Daniel, Martini Alberto, De Benedetti Fabrizio, Paediatric Rheumatology International Trials Organisation PRINTO, Pediatric Rheumatology Collaborative Study Group (PRCSG). Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.. Annals of the rheumatic diseases. 2014. DOI: 10.1136/annrheumdis-2014-205351.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.